Apply for Funding
CPRIT offers several funding opportunities for promising cancer research, product development, and prevention programs. All funding opportunities are announced through formal Requests for Applications (RFAs) and applications must be submitted through the online application receipt system.
Learn more about the grants process.
Cancer Screening and Early Detection
Program | Prevention |
RFA Status | Open |
Description |
This award mechanism seeks to support the delivery of evidence-based clinical services to screen for cancer and pre-cancer in underserved populations who do not have adequate access to cancer early detection interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community, have nationally recommended screening methods, and use evidence-based methods to screen for these cancers. Award: Maximum of $1M for new projects and $2.5M for expansion projects Duration: Maximum 60 months |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | May 05, 2023 |
Application Receipt | June 01, 2023 - August 30, 2023 |
Application Review | Continuous |
Award Notification | February 2024 |
Primary Prevention of Cancer
Program | Prevention |
RFA Status | Open |
Description |
This award mechanism focuses on increasing implementation of evidence-based strategies to ensure that all Texans benefit from the cancer prevention knowledge that we currently have. CPRIT seeks to fund multilevel interventions to reduce cancer risk, disease burden, and cancer disparities. Modifiable risk behaviors include tobacco use, obesity, physical inactivity, unhealthy eating, alcohol use, sun exposure, HPV vaccination, Hepatitis B vaccination, and environmental/ occupational cancer exposures. Applications should also assess and address social determinants that contribute to cancer burden and disparities (e.g., cultural factors, unmet needs, access barriers). Interventions and communications should be structured to address the unique circumstances of the population to be served.
Duration: Maximum 60 months |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | May 05, 2023 |
Application Receipt | June 01, 2023 - August 30, 2023 |
Application Review | Continuous |
Award Notification | February 2024 |
SEED Awards
Program | Product Development Research |
RFA Status | Open |
Description |
Funding available through this RFA supports company formation, as well as early research and development of novel oncology therapeutics, devices, treatment-oriented information technology products, diagnostics, or tools. The objective of the SEED Award program is to start with an interesting technology and to progress it toward a commercially viable business opportunity, i.e., make it more attractive to private funding agents. Typically, applicants have completed the following activities:
Award Maximum: $3 million Duration: Maximum of 36 months |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | May 01, 2023 |
Application Receipt | May 01, 2023 - June 30, 2023 |
Application Review | Continuous |
Award Notification | Continuous |
Texas Diagnostic and Devices Company Awards
Program | Product Development Research |
RFA Status | Open |
Description |
Funding available through this RFA supports the ongoing research and development of diagnostic tests and devices to treat, detect, diagnose, monitor, and assist in the treatment of cancer. Relevant areas include:
Generally, at the time that an applicant applies to CPRIT pursuant to this RFA, the company has developed a commercial prototype of the device or a pictorial representation of the functional components/elements of the device. With respect to diagnostics, the company has developed assays that work on human samples and whose importance is well justified for development into clinical assays. The applicant should be working toward submitting an Investigational Device Exemption (IDE) or a 510(k) or Premarketing Approval (PMA) and is typically within one year from filing an IDE (or later stage work.) Potential applicants that are not at or near this stage of product development should consider applying for a Texas Seed Company Award. With appropriate justification, companies may use CPRIT funds to support studies that establish preclinical proof of concept, product validation, design, production, manufacturing and development, and clinical studies demonstrating safety and efficacy. Award Maximum: None Duration: Maximum 36 months |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | May 01, 2023 |
Application Receipt | May 01, 2023 - June 30, 2023 |
Application Review | Continuous |
Award Notification | Continuous |
Texas New Technologies Company Awards
Program | Product Development Research |
RFA Status | Open |
Description |
Funding available through this RFA supports the ongoing research and development of new and emerging technologies for the detection, diagnosis, prognosis, monitoring, or treatment of cancer. CPRIT created this RFA to fund new and emerging technology projects that do not easily fit into any of the three other CPRIT Product Development Research RFAs. Proposals may include, but are not limited to, bioinformatics, artificial intelligence, production of radionuclides or their precursors, manufacture of cell-based therapies, processes to improve the quality of the samples used for cancer research or clinical care, and biomanufacturing of therapeutics. With appropriate justification, companies may use CPRIT funds to support studies that establish preclinical proof of concept, product validation, design, production, manufacturing and development, and clinical studies demonstrating safety and efficacy. Award Maximum: None Duration: Maximum of 36 months |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | May 01, 2023 |
Application Receipt | May 01, 2023 - June 30, 2023 |
Application Review | Continuous |
Award Notification | Continuous |
Texas Therapeutics Company Awards
Program | Product Development Research |
RFA Status | Open |
Description |
Funding available through this RFA supports the ongoing research and development of innovative products, services, and infrastructure with significant potential impact on patient care. Generally, at this stage, the company has identified and characterized a lead compound; demonstrated efficacy in multiple translationally relevant animal models; completed pilot/dose ranging toxicology studies; determined the feasibility of a scalable, GMP compliant manufacturing process, including release assays; and identified a prototype formulation suitable for further development. The applicant is typically within one year from filing an IND/IDE or already in Phase 1.
Award Maximum: None Duration: Maximum of 36 months |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | May 01, 2023 |
Application Receipt | May 01, 2023 - June 30, 2023 |
Application Review | Continuous |
Award Notification | Continuous |
Individual Investigator Research Awards
Revised: 05/16/2023
Instructions for Applicants
Revised: 05/16/2023
Program | Academic Research |
RFA Status | Open |
Description |
Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. Areas of interest include laboratory research, translational studies, and/or clinical investigations. Competitive renewal applications accepted. Award: Up to $350,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years. |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | February 17, 2023 |
Application Receipt | March 15, 2023 - June 14, 2023 |
Application Review | June 2023 - February 2024 |
Award Notification | February 2024 |
Individual Investigator Research Awards for Cancer in Children and Adolescents
Revised: 05/16/2023
Instructions for Applicants
Revised: 05/16/2023
Program | Academic Research |
RFA Status | Open |
Description |
Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Competitive renewal applications accepted. Award: Up to $350,000 per year. Applicants that plan on conducting a clinical trial as part of the project may request up to $500,000 in total costs. Exceptions permitted if extremely well justified; maximum duration: 4 years. |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | February 17, 2023 |
Application Receipt | March 15, 2023 - June 14, 2023 |
Application Review | June 2023 - February 2024 |
Award Notification | February 2024 |
Individual Investigator Research Awards for Clinical Translation
Revised: 05/16/2023
Instructions for Applicants
Revised: 05/16/2023
Program | Academic Research |
RFA Status | Open |
Description |
Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Clinical trial must be planned to begin when contract is awarded.
Award: Up to $500,000 per year. Maximum duration: 4 years. Exceptions permitted if extremely well justified. |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | February 17, 2023 |
Application Receipt | March 15, 2023 - June 14, 2023 |
Application Review | June 2023 - February 2024 |
Award Notification | February 2024 |
Individual Investigator Research Awards for Computational Systems Biology of Cancer
Revised: 05/16/2023
Instructions for Applicants
Revised: 05/16/2023
Program | Academic Research |
RFA Status | Open |
Description |
Supports applications for innovative mathematical and/or computational research projects addressing questions that will advance current knowledge in the (a) mechanisms that tie altered gene expression and downstream molecular mechanisms to functional cancer phenotypes and/or (b) mechanisms that tie tumor morphology to functional cancer phenotypes and/or mechanisms that tie treatment sequence and combination to evolving functional cancer phenotypes (that emerge as a result of treatment selection).
Award: Up to $400,000 in total costs per year for up to 3 years. Exceptions permitted if extremely well justified. |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | February 17, 2023 |
Application Receipt | March 15, 2023 - June 14, 2023 |
Application Review | June 2023 - February 2024 |
Award Notification | February 2024 |
Individual Investigator Research Awards for Prevention and Early Detection
Revised: 05/16/2023
Instructions for Applicants
Revised: 05/16/2023
Program | Academic Research |
RFA Status | Open |
Description |
Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded Texas Collaborative Center for Hepatocellular Cancer (https://www.bcm.edu/research/labs-and-centers/research-centers/texas-collaborative-center-for-hepatocellular-cancer) are strongly encouraged.
Award: Up to $400,000 per year. Exceptions permitted if extremely well justified; maximum duration: 5 years. |
Review Cycle | Fiscal Year 2024 - Cycle 1 |
RFA Release | February 17, 2023 |
Application Receipt | March 15, 2023 - June 14, 2023 |
Application Review | June 2023 - February 2024 |
Award Notification | February 2024 |
Recruitment of First-Time, Tenure-Track Faculty Members
Program | Academic Research |
RFA Status | Open |
Description |
Supports very promising emerging investigators, pursuing their first faculty appointment in Texas, who have the ability to make outstanding contributions to the field of cancer research. Award: Up to $2 million over a period of five years. |
Review Cycle | Fiscal Year 2023 - Cycle 1 |
RFA Release | June 21, 2022 |
Application Receipt | June 21, 2022 - June 20, 2023 |
Application Review | September 2022 - July 2023 |
Award Notification | Continuous |
Recruitment of Established Investigators
Program | Academic Research |
RFA Status | Open |
Description |
Recruits outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas. Award: Up to $6 million over a period of five years. |
Review Cycle | Fiscal Year 2023 - Cycle 1 |
RFA Release | June 21, 2022 |
Application Receipt | June 21, 2022 - June 20, 2023 |
Application Review | September 2022 - July 2023 |
Award Notification | Continuous |

Coronavirus (COVID-19): Guidance for CPRIT Grantees and Grant Applicants